Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33

European Journal of Immunology

Volumn 45, Issue 11, 2015, Pages 3034-3044

  Bandara, Geethani ^a   Beaven, Michael A ^b   Olivera, Ana ^a   Gilfillan, Alasdair M ^a   Metcalfe, Dean D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Antigen; Human mast cells; IL 33; SST2; Stem cell factor

Indexed keywords

INTERLEUKIN 1 RECEPTOR LIKE 1; INTERLEUKIN 33; INTERLEUKIN RECEPTOR; SILVER; STEM CELL FACTOR; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; IL1RL1 PROTEIN, MOUSE; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN;

ANAPHYLAXIS; ANIMAL CELL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; INFLAMMATION; MAST CELL; NONHUMAN; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CELL CULTURE; FLOW CYTOMETRY; IMMUNOBLOTTING; IMMUNOLOGY; METABOLISM; MOUSE; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANIMALS; CELLS, CULTURED; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; INFLAMMATION; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTERLEUKIN-33; MAST CELLS; MICE; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CELL SURFACE; RECEPTORS, INTERLEUKIN; SIGNAL TRANSDUCTION;

EID: 84951566841     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201545501     Document Type: Article

References (70)

1. Kondo, Y., Yoshimoto, T., Yasuda, K., Futatsugi-Yumikura, S., Morimoto, M., Hayashi, N., Hoshino, T. et al., Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int. Immunol. 2008. 20: 791-800.
2. Smithgall, M. D., Comeau, M. R., Yoon, B. R., Kaufman, D., Armitage, R. and Smith, D. E., IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int. Immunol. 2008. 20: 1019-1030.
3. Kurowska-Stolarska, M., Stolarski, B., Kewin, P., Murphy, G., Corrigan, C. J., Ying, S., Pitman, N. et al., IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J. Immunol. 2009. 183: 6469-6477.
4. Haenuki, Y., Matsushita, K., Futatsugi-Yumikura, S., Ishii, K. J., Kawagoe, T., Imoto, Y., Fujieda, S. et al., A critical role of IL-33 in experimental allergic rhinitis. J. Allergy Clin. Immunol. 2012. 130: 184-194, e111.
5. Matsuba-Kitamura, S., Yoshimoto, T., Yasuda, K., Futatsugi-Yumikura, S., Taki, Y., Muto, T., Ikeda, T. et al., Contribution of IL-33 to induction and augmentation of experimental allergic conjunctivitis. Int. Immunol. 2010. 22: 479-489.
6. Savinko, T., Matikainen, S., Saarialho-Kere, U., Lehto, M., Wang, G., Lehtimaki, S., Karisola, P. et al., IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J. Invest. Dermatol. 2012. 132: 1392-1400.
7. Cevikbas, F. and Steinhoff, M., IL-33: a novel danger signal system in atopic dermatitis. J. Invest. Dermatol. 2012. 132: 1326-1329.
8. Palmer, G. and Gabay, C., Interleukin-33 biology with potential insights into human diseases. Nat. Rev. Rheumatol. 2011. 7: 321-329.
9. Liew, F. Y., Pitman, N. I. and McInnes, I. B., Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 2010. 10: 103-110.
10. Pei, C., Barbour, M., Fairlie-Clarke, K. J., Allan, D., Mu, R. and Jiang, H. R., Emerging role of interleukin-33 in autoimmune diseases. Immunology 2014. 141: 9-17.
11. Lunderius-Andersson, C., Enoksson, M. and Nilsson, G., Mast cells respond to cell injury through the recognition of IL-33. Front. Immunol. 2012. 3: 82.
12. Baekkevold, E. S., Roussigne, M., Yamanaka, T., Johansen, F. E., Jahnsen, F. L., Amalric, F., Brandtzaeg, P. et al., Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am. J. Pathol. 2003. 163: 69-79.
13. Carriere, V., Roussel, L., Ortega, N., Lacorre, D. A., Americh, L., Aguilar, L., Bouche, G. et al., IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl. Acad. Sci. USA 2007. 104: 282-287.
14. Roussel, L., Erard, M., Cayrol, C. and Girard, J. P., Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep. 2008. 9: 1006-1012.
15. Bianchi, M. E., DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 2007. 81: 1-5.
16. Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T. K., Zurawski, G. et al., IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005. 23: 479-490.
17. Ho, L. H., Ohno, T., Oboki, K., Kajiwara, N., Suto, H., Iikura, M., Okayama, Y. et al., IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcεRI signals. J. Leukoc. Biol. 2007. 82: 1481-1490.
18. Iikura, M., Suto, H., Kajiwara, N., Oboki, K., Ohno, T., Okayama, Y., Saito, H. et al., IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab. Invest. 2007. 87: 971-978.
19. Stolarski, B., Kurowska-Stolarska, M., Kewin, P., Xu, D. and Liew, F. Y., IL-33 exacerbates eosinophil-mediated airway inflammation. J. Immunol. 2010. 185: 3472-3480.
20. + lymphoid cells. Nature 2010. 463: 540-544.
21. Neill, D. R., Wong, S. H., Bellosi, A., Flynn, R. J., Daly, M., Langford, T. K., Bucks, C. et al., Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010. 464: 1367-1370.
22. Allakhverdi, Z., Smith, D. E., Comeau, M. R. and Delespesse, G., Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J. Immunol. 2007. 179: 2051-2054.
23. Komai-Koma, M., Xu, D., Li, Y., McKenzie, A. N., McInnes, I. B. and Liew, F. Y., IL-33 is a chemoattractant for human Th2 cells. Eur. J. Immunol. 2007. 37: 2779-2786.
24. Silver, M. R., Margulis, A., Wood, N., Goldman, S. J., Kasaian, M. and Chaudhary, D., IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation. Inflamm. Res. 2010. 59: 207-218.
25. Andrade, M. V., Iwaki, S., Ropert, C., Gazzinelli, R. T., Cunha-Melo, J. R. and Beaven, M. A., Amplification of cytokine production through synergistic activation of NFAT and AP-1 following stimulation of mast cells with antigen and IL-33. Eur. J. Immunol. 2011. 41: 760-772.
26. Lefrancais, E., Duval, A., Mirey, E., Roga, S., Espinosa, E., Cayrol, C. and Girard, J. P., Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells. Proc. Natl. Acad. Sci. USA 2014. 111: 15502-15507.
27. Martin, M. U., Special aspects of interleukin-33 and the IL-33 receptor complex. Semin. Immunol. 2013. 25: 449-457.
28. Iwahana, H., Yanagisawa, K., Ito-Kosaka, A., Kuroiwa, K., Tago, K., Komatsu, N., Katashima, R. et al., Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur. J. Biochem. 1999. 264: 397-406.
29. Bergers, G., Reikerstorfer, A., Braselmann, S., Graninger, P. and Busslinger, M., Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J. 1994. 13: 1176-1188.
30. Hayakawa, H., Hayakawa, M., Kume, A. and Tominaga, S., Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J. Biol. Chem. 2007. 282: 26369-26380.
31. Leung, B. P., Xu, D., Culshaw, S., McInnes, I. B. and Liew, F. Y., A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J. Immunol. 2004. 173: 145-150.
32. Ohto-Ozaki, H., Kuroiwa, K., Mato, N., Matsuyama, Y., Hayakawa, M., Tamemoto, H. and Tominaga, S., Characterization of ST2 transgenic mice with resistance to IL-33. Eur. J. Immunol. 2010. 40: 2632-2642.
33. Oshikawa, K., Kuroiwa, K., Tago, K., Iwahana, H., Yanagisawa, K., Ohno, S., Tominaga, S. I. et al., Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am. J. Respir. Crit. Care Med. 2001. 164: 277-281.
34. Ali, M., Zhang, G., Thomas, W. R., McLean, C. J., Bizzintino, J. A., Laing, I. A., Martin, A. C. et al., Investigations into the role of ST2 in acute asthma in children. Tissue Antigens 2009. 73: 206-212.
35. Shimizu, M., Matsuda, A., Yanagisawa, K., Hirota, T., Akahoshi, M., Inomata, N., Ebe, K. et al., Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum. Mol. Genet. 2005. 14: 2919-2927.
36. Hong, Y. S., Moon, S. J., Joo, Y. B., Jeon, C. H., Cho, M. L., Ju, J. H., Oh, H. J. et al., Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J. Korean Med. Sci. 2011. 26: 1132-1139.
37. Talabot-Ayer, D., McKee, T., Gindre, P., Bas, S., Baeten, D. L., Gabay, C. and Palmer, G., Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine 2012. 79: 32-37.
38. Diaz-Jimenez, D., Nunez, L. E., Beltran, C. J., Candia, E., Suazo, C., Alvarez-Lobos, M., Gonzalez, M. J. et al., Soluble ST2: a new and promising activity marker in ulcerative colitis. World J. Gastroenterol. 2011. 17: 2181-2190.
39. Mok, M. Y., Huang, F. P., Ip, W. K., Lo, Y., Wong, F. Y., Chan, E. Y., Lam, K. F. et al., Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology 2010. 49: 520-527.
40. Moritz, D. R., Rodewald, H. R., Gheyselinck, J. and Klemenz, R., The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J. Immunol. 1998. 161: 4866-4874.
41. Hsu, C. L., Neilsen, C. V. and Bryce, P. J., IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS One 2010. 5: e11944.
42. Baba, Y., Maeda, K., Yashiro, T., Inage, E., Kasakura, K., Suzuki, R., Niyonsaba, F. et al., GATA2 is a critical transactivator for the human IL1RL1/ST2 promoter in mast cells/basophils: opposing roles for GATA2 and GATA1 in human IL1RL1/ST2 gene expression. J. Biol. Chem. 2012. 287: 32689-32696.
43. Salari, H. and Chan-Yeung, M., Interleukin-1 potentiates antigen-mediated arachidonic acid metabolite formation in mast cells. Clin. Exp. Allergy 1989. 19: 637-641.
44. Lu-Kuo, J. M., Austen, K. F. and Katz, H. R., Post-transcriptional stabilization by interleukin-1β of interleukin-6 mRNA induced by c-kit ligand and interleukin-10 in mouse bone marrow-derived mast cells. J. Biol. Chem. 1996. 271: 22169-22174.
45. Sasaki, Y., Yoshimoto, T., Maruyama, H., Tegoshi, T., Ohta, N., Arizono, N. and Nakanishi, K., IL-18 with IL-2 protects against Strongyloides venezuelensis infection by activating mucosal mast cell-dependent type 2 innate immunity. J. Exp. Med. 2005. 202: 607-616.
46. Wiener, Z., Pocza, P., Racz, M., Nagy, G., Tolgyesi, G., Molnar, V., Jaeger, J. et al., IL-18 induces a marked gene expression profile change and increased Ccl1 (I-309) production in mouse mucosal mast cell homologs. Int. Immunol. 2008. 20: 1565-1573.
47. Hundley, T. R., Gilfillan, A. M., Tkaczyk, C., Andrade, M. V., Metcalfe, D. D. and Beaven, M. A., Kit and FcεRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells. Blood 2004. 104: 2410-2417.
48. Drube, S., Heink, S., Walter, S., Lhn, T., Grusser, M., Gerbaulet, A., Berod, L. et al., The receptor tyrosine c-Kit controls IL-33 receptor signaling in mast cells. Blood 2010. 115: 3899-3906.
49. Hsu, C. L. and Bryce, P. J., Inducible IL-33 expression by mast cells is regulated by a calcium-dependent pathway. J. Immunol. 2012. 189: 3421-3429.
50. Hudson, C. A., Christophi, G. P., Gruber, R. C., Wilmore, J. R., Lawrence, D. A. and Massa, P. T., Induction of IL-33 expression and activity in central nervous system glia. J. Leukoc. Biol. 2008. 84: 631-643.
51. Kouzaki, H., Iijima, K., Kobayashi, T., O'Grady, S. M. and Kita, H., The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J. Immunol. 2011. 186: 4375-4387.
52. Enoksson, M., Lyberg, K., Moller-Westerberg, C., Fallon, P. G., Nilsson, G. and Lunderius-Andersson, C., Mast cells as sensors of cell injury through IL-33 recognition. J. Immunol. 2011. 186: 2523-2528.
53. Drube, S., Heink, S., Walter, S., Lohn, T., Grusser, M., Gerbaulet, A., Berod, L. et al., The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells. Blood 2010. 115: 3899-3906.
54. Olivera, A. and Rivera, J., Paradigm shifts in mast cell and basophil biology and function: an emerging view of immune regulation in health and disease. Methods Mol. Biol. 2014. 1192: 3-31.
55. Hagaman, D. D., Okayama, Y., D'Ambrosio, C., Prussin, C., Gilfillan, A. M. and Metcalfe, D. D., Secretion of interleukin-1 receptor antagonist from human mast cells after immunoglobulin E-mediated activation and after segmental antigen challenge. Am. J. Respir. Cell. Mol. Biol. 2001. 25: 685-691.
56. Sandler, C., Lindstedt, K. A., Joutsiniemi, S., Lappalainen, J., Juutilainen, T., Kolah, J., Kovanen, P. T. et al., Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-alpha, IL-1beta and IL-1Ra. Inflamm. Res. 2007. 56: 230-239.
57. Hershko, A. Y., Suzuki, R., Charles, N., Alvarez-Errico, D., Sargent, J. L., Laurence, A. and Rivera, J., Mast cell interleukin-2 production contributes to suppression of chronic allergic dermatitis. Immunity 2011. 35: 562-571.
58. Ganeshan, K., Johnston, L. K. and Bryce, P. J., TGF-β1 limits the onset of innate lung inflammation by promoting mast cell-derived IL-6. J. Immunol. 2013. 190: 5731-5738.
59. Grimbaldeston, M. A., Nakae, S., Kalesnikoff, J., Tsai, M. and Galli, S. J., Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat. Immunol. 2007. 8: 1095-1104.
60. Caughey, G. H., Mast cell proteases as protective and inflammatory mediators. Adv. Exp. Med. Biol. 2011. 716: 212-234.
61. Jung, M. Y., Smrz, D., Desai, A., Bandara, G., Ito, T., Iwaki, S., Kang, J. H. et al., IL-33 induces a hyporesponsive phenotype in human and mouse mast cells. J. Immunol. 2013. 190: 531-538.
62. Gudbjartsson, D. F., Bjornsdottir, U. S., Halapi, E., Helgadottir, A., Sulem, P., Jonsdottir, G. M., Thorleifsson, G. et al., Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat. Genet. 2009. 41: 342-347.
63. Akhabir, L. and Sandford, A., Genetics of interleukin 1 receptor-like 1 in immune and inflammatory diseases. Curr. Genomics 2010. 11: 591-606.
64. Ho, J. E., Chen, W. Y., Chen, M. H., Larson, M. G., McCabe, E. L., Cheng, S., Ghorbani, A. et al., Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling. J. Clin. Invest. 2013. 123: 4208-4218.
65. Kuehn, H. S., Radinger, M. and Gilfillan, A. M., Measuring mast cell mediator release. Curr. Protoc. Immunol. 2010. 7: Unit7.38.
66. +, and expresses aminopeptidase N (CD13). Blood 1999. 94: 2333-2342.
67. + pluripotent progenitor cells. Methods Mol. Biol. 2006. 315: 105-112.
68. Kirshenbaum, A. S., Akin, C., Wu, Y., Rottem, M., Goff, J. P., Beaven, M. A., Rao, V. K. et al., Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcεRI or FcγRI. Leuk. Res. 2003. 27: 677-682.
69. Tkaczyk, C., Beaven, M. A., Brachman, S. M., Metcalfe, D. D. and Gilfillan, A. M., The phospholipase Cγ1 -dependent pathway of FcεRI-mediated mast cell activation is regulated independently of phosphatidylinositol 3-kinase. J. Biol. Chem. 2003. 278: 48474-48484.
70. Tkaczyk, C., Metcalfe, D. D. and Gilfillan, A. M., Determination of protein phosphorylation in FcεRI-activated human mast cells by immunoblot analysis requires protein extraction under denaturing conditions. J. Immunol. Methods 2002. 268: 239-243.